{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:16:48Z","timestamp":1790705808435,"version":"4.1.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:sec id=\"ab-hoi230031-4\"><jats:title>Importance<\/jats:title><jats:p>Syncope is the most powerful predictor for subsequent life-threatening events (LTEs) in patients with congenital long QT syndrome (LQTS). Whether distinct syncope triggers are associated with differential subsequent risk of LTEs is unknown.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230031-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate the association between adrenergic (AD)\u2013 and nonadrenergic (non\u2013AD)-triggered syncopal events and the risk of subsequent LTEs in patients with LQT types 1 to 3 (LQT1-3).<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230031-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective cohort study included data from 5 international LQTS registries (Rochester, New York; the Mayo Clinic, Rochester, Minnesota; Israel, the Netherlands, and Japan). The study population comprised 2938 patients with genetically confirmed LQT1, LQT2, or LQT3 stemming from a single LQTS-causative variant. Patients were enrolled from July 1979 to July 2021.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230031-7\"><jats:title>Exposures<\/jats:title><jats:p>Syncope by AD and non-AD triggers.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230031-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end point was the first occurrence of an LTE. Multivariate Cox regression was used to determine the association of AD- or non\u2013AD-triggered syncope on the risk of subsequent LTE by genotype. Separate analysis was performed in patients with \u03b2-blockers.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230031-9\"><jats:title>Results<\/jats:title><jats:p>A total of 2938 patients were included (mean [SD] age at enrollment, 29 [7] years; 1645 [56%] female). In 1331 patients with LQT1, a first syncope occurred in 365 (27%) and was induced mostly with AD triggers (243 [67%]). Syncope preceded 43 subsequent LTEs (68%). Syncopal episodes associated with AD triggers were associated with the highest risk of subsequent LTE (hazard ratio [HR], 7.61; 95% CI, 4.18-14.20; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), whereas the risk associated with syncopal events due to non-AD triggers was statistically nonsignificant (HR, 1.50; 95% CI, 0.21-4.77; <jats:italic>P<\/jats:italic>\u2009=\u2009.97). In 1106 patients with LQT2, a first syncope occurred in 283 (26%) and was associated with AD and non-AD triggers in 106 (37%) and 177 (63%), respectively. Syncope preceded 55 LTEs (56%). Both AD- and non\u2013AD-triggered syncope were associated with a greater than 3-fold increased risk of subsequent LTE (HR, 3.07; 95% CI, 1.66-5.67; <jats:italic>P<\/jats:italic>\u2009\u2264\u2009.001 and HR, 3.45, 95% CI, 1.96-6.06; <jats:italic>P<\/jats:italic>\u2009\u2264\u2009.001, respectively). In contrast, in 501 patients with LQT3, LTE was preceded by a syncopal episode in 7 (12%). In patients with LQT1 and LQT2, treatment with \u03b2-blockers following a syncopal event was associated with a significant reduction in the risk of subsequent LTEs. The rate of breakthrough events during treatment with \u03b2-blockers was significantly higher among those treated with selective agents vs nonselective agents.<\/jats:p><\/jats:sec><jats:sec id=\"ab-hoi230031-10\"><jats:title>Conclusion and Relevance<\/jats:title><jats:p>In this study, trigger-specific syncope in LQTS patients was associated with differential risk of subsequent LTE and response to \u03b2-blocker therapy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2023.1951","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T15:03:48Z","timestamp":1689174228000},"page":"775","source":"Crossref","is-referenced-by-count":15,"title":["Association Between Syncope Trigger Type and Risk of Subsequent Life-Threatening Events in Patients With Long QT Syndrome"],"prefix":"10.1001","volume":"8","author":[{"given":"Arwa","family":"Younis","sequence":"first","affiliation":[{"name":"Cardiac Electrophysiology Section, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"},{"name":"Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Martijn","family":"Bos","sequence":"additional","affiliation":[{"name":"Divisions of Heart Rhythm Services and Pediatric Cardiology, Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Genetic Heart Rhythm Clinic and Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Zareba","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet K.","family":"Aktas","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur A. M.","family":"Wilde","sequence":"additional","affiliation":[{"name":"Heart Center, Amsterdam Cardiovascular Sciences, Department of Clinical and Experimental Cardiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands"},{"name":"European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Tabaja","sequence":"additional","affiliation":[{"name":"Cardiac Electrophysiology Section, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bodurian","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Tobert","sequence":"additional","affiliation":[{"name":"Divisions of Heart Rhythm Services and Pediatric Cardiology, Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Genetic Heart Rhythm Clinic and Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"McNitt","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronislava","family":"Polonsky","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Ackerman","sequence":"additional","affiliation":[{"name":"Divisions of Heart Rhythm Services and Pediatric Cardiology, Departments of Cardiovascular Medicine, Pediatric and Adolescent Medicine, and Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Genetic Heart Rhythm Clinic and Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"Clinical Cardiovascular Research Center, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"24","key":"hoi230031r1","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/j.jacc.2008.02.068","article-title":"Long QT syndrome.","volume":"51","author":"Goldenberg","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi230031r2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1161\/01.CIR.103.1.89","article-title":"Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.","volume":"103","author":"Schwartz","year":"2001","journal-title":"Circulation"},{"issue":"2","key":"hoi230031r3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5339\/gcsp.2015.26","article-title":"Genotype-phenotype correlation in long QT syndrome.","volume":"2015","author":"Baskar","year":"2015","journal-title":"Glob Cardiol Sci Pract"},{"issue":"8","key":"hoi230031r4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S0002-9149(99)00458-0","article-title":"Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome.","volume":"84","author":"Moss","year":"1999","journal-title":"Am J Cardiol"},{"issue":"17","key":"hoi230031r5","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1161\/CIRCULATIONAHA.107.701243","article-title":"Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome.","volume":"117","author":"Goldenberg","year":"2008","journal-title":"Circulation"},{"issue":"10","key":"hoi230031r6","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/jama.296.10.1249","article-title":"Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome.","volume":"296","author":"Hobbs","year":"2006","journal-title":"JAMA"},{"issue":"8","key":"hoi230031r7","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jacc.2009.11.042","article-title":"Risk of fatal arrhythmic events in long QT syndrome patients after syncope.","volume":"55","author":"Jons","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"hoi230031r8","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1161\/01.CIR.102.10.1178","article-title":"Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.","volume":"102","author":"Splawski","year":"2000","journal-title":"Circulation"},{"issue":"9","key":"hoi230031r9","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.hrthm.2009.05.021","article-title":"Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test.","volume":"6","author":"Kapplinger","year":"2009","journal-title":"Heart Rhythm"},{"issue":"1","key":"hoi230031r10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jacc.2004.03.043","article-title":"Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan.","volume":"44","author":"Shimizu","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"hoi230031r11","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1161\/CIRCULATIONAHA.111.048041","article-title":"Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to \u00df-blocker therapy in type 1 long-QT syndrome.","volume":"125","author":"Barsheshet","year":"2012","journal-title":"Circulation"},{"issue":"30","key":"hoi230031r12","doi-asserted-by":"publisher","first-page":"21063","DOI":"10.1074\/jbc.274.30.21063","article-title":"Long QT syndrome-associated mutations in the S4-S5 linker of KvLQT1 potassium channels modify gating and interaction with minK subunits.","volume":"274","author":"Franqueza","year":"1999","journal-title":"J Biol Chem"},{"issue":"1","key":"hoi230031r13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4161\/chan.4.1.10227","article-title":"PKA and PKC partially rescue long QT type 1 phenotype by restoring channel-PIP2 interactions.","volume":"4","author":"Matavel","year":"2010","journal-title":"Channels (Austin)"},{"issue":"11","key":"hoi230031r14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1001\/jama.292.11.1341","article-title":"Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers.","volume":"292","author":"Priori","year":"2004","journal-title":"JAMA"},{"issue":"12","key":"hoi230031r15","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.hrthm.2010.09.011","article-title":"Trigger-specific risk factors and response to therapy in long QT syndrome type 2.","volume":"7","author":"Kim","year":"2010","journal-title":"Heart Rhythm"},{"issue":"22","key":"hoi230031r16","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.jacc.2009.08.028","article-title":"Genotype-phenotype aspects of type 2 long QT syndrome.","volume":"54","author":"Shimizu","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"hoi230031r17","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1056\/NEJM199810013391404","article-title":"Influence of the genotype on the clinical course of the long-QT syndrome.","volume":"339","author":"Zareba","year":"1998","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi230031r18","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/CIRCULATIONAHA.116.021823","article-title":"Clinical aspects of type 3 long-QT syndrome.","volume":"134","author":"Wilde","year":"2016","journal-title":"Circulation"},{"issue":"10","key":"hoi230031r19","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.","volume":"15","author":"Al-Khatib","year":"2018","journal-title":"Heart Rhythm"},{"issue":"41","key":"hoi230031r20","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"issue":"37","key":"hoi230031r21","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1093\/eurheartj\/ehz228","article-title":"Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality.","volume":"40","author":"Weeke","year":"2019","journal-title":"Eur Heart J"},{"issue":"22","key":"hoi230031r22","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1093\/eurheartj\/ehac134","article-title":"Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias.","volume":"43","author":"Schwartz","year":"2022","journal-title":"Eur Heart J"},{"issue":"9","key":"hoi230031r23","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jacc.2015.12.033","article-title":"Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3.","volume":"67","author":"Mazzanti","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hoi230031r24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.118.007280","article-title":"Mexiletine shortens the QT interval in patients with potassium channel-mediated type 2 long QT syndrome.","volume":"12","author":"Bos","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"3","key":"hoi230031r25","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/jce.v32.3","article-title":"Efficacy of intentional permanent atrial pacing in the long-term management of congenital long QT syndrome.","volume":"32","author":"Kowlgi","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"21","key":"hoi230031r26","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.jacc.2021.09.017","article-title":"Effectiveness of implantable cardioverter-defibrillators to reduce mortality in patients with long QT syndrome.","volume":"78","author":"Wang","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2806499\/jamacardiology_younis_2023_oi_230031_1690482619.94792.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T15:03:01Z","timestamp":1691593381000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2806499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.1951","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}